Business Wire

NE-ADJUVANCE-TECH

Share
Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant

Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. This is the first clinical trial of a candidate from the company’s adjuvant and vaccine portfolio.

“The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. Our semi-synthetic molecule is designed to overcome these limitations,” said Tyler Martin M.D., Chief Executive Officer at Adjuvance. “These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.”

Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine. Solicited events reported by subjects included mild to moderate injection site reactions and mild or moderate systemic symptoms at a frequency similar to the commercial vaccine. No serious adverse events were reported.

The ongoing phase 1, randomized, double-blind, active-controlled, dose-escalation study is assessing the safety and immunogenicity of P ertussis A cellular V accine A djuvanted with TQL-1055 (PAVA). It has fully enrolled 72 healthy adults 18-50 years of age and is evaluating six escalating dose levels from 25 to 800 mcg of TQL-1055, co-administered with a commercial pertussis vaccine. The primary endpoints of the study are safety and tolerability. Further data will be presented at IDWeek 2021.

About Pertussis: Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination.

About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21 that is designed to have improved tolerability and provide the same strong immune response as QS-21. Adjuvance has retained the desirable properties of, and eliminated several challenges with QS-21. TQL-1055 is a semi-synthetic molecule whose efficient synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.

About saponin adjuvants : Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against shingles, malaria, COVID-19 and influenza. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.

About Adjuvance Technologies : Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.

Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Talent shortages and AI pressures drive shifting dynamics in global technology leadership, According to Expereo16.9.2025 10:00:00 CEST | Press release

Skills gaps in networking, cybersecurity, and AI are delaying growth and forcing businesses to rethink leadership, training, and investment strategies Global businesses are facing mounting challenges in their growth ambitions due to persistent skills shortages in critical technology areas. As AI becomes more deeply embedded in business strategy, organisations are struggling to find or retain talent in key domains such as networking (39%), cybersecurity (40%), and Data/AI/automation (33%). The findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” The report reveals that 39% of organisations are struggling to find or retain networking talent, while 33% report similar challenges in data, AI, and automation - figures that remain consistent with 2024 findings. These shortages are not only slowing down AI adoption but also reshaping leadership dynamics and workforce strategies across enterpris

Infobip Achieves GSMA Open Gateway Certifications for Network APIs16.9.2025 10:00:00 CEST | Press release

New credentials strengthen Infobip's role in the global telco ecosystem Global communications platform Infobiphas received two new Network API certifications from the GSMA, as part of the CAMARA project. The SIM Swap and Number Verification certifications demonstrate Infobip's commitment to advancing global standards for Network APIs through the GSMA Open Gateway initiative. The certifications mark a significant milestone for Infobip and its telco partners worldwide. The certifications validate Infobip's expertise and support mobile network operators (MNOs) in achieving their own certifications as part of GSMA's global standardization efforts. Viktorija Radman, Telecom Growth & Strategy Director at Infobip, said:"Achieving GSMA certifications for SIM Swap and Number Verification demonstrates our commitment to building secure, scalable solutions for operators worldwide. As a CPaaS enabler, Infobip is dedicated to helping telcos embrace new global standards and bring the benefits of Netw

Groundbreaking New Sensor Transforms How Europe Tracks Pollution, Smoke and Cloud From Space16.9.2025 09:00:00 CEST | Press release

The first images from the Multi-Viewing, Multi-Channel, Multi-Polarisation Imager, presented at the 2025 EUMETSAT Conference, reveal the brand-new instrument’s exceptional ability to monitor the Earth’s atmosphere from multiple perspectives, to support improved forecasts and air pollution and climate monitoring. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915322837/en/ 3MI’s very first image, captured between 10:59 and 11:03 CEST on 28 August 2025, confirmed the instrument is already performing well as it delivers its preliminary data streams. The left panel shows a standard view using natural light, highlighting clouds and land surfaces. The right panel, based on polarised light measurements, reveals much finer detail of the atmosphere’s composition – such as subtle cloud structures over Italy and wildfire smoke on the right edge of the image, over Greece. When sunlight interacts with particles in the air, like drople

iBASIS and XLSMART Announce Strategic Management Service Agreement to Manage International and Domestic Mobile Authentication Traffic16.9.2025 09:00:00 CEST | Press release

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and PT XLSMART Telecom Sejahtera Tbk (XLSMART), formerly known as PT XL Axiata Tbk and PT Smartfren Telecom Tbk, today announced the signing of a Management Service Agreement designed to enhance the efficiency and security of Mobile Authentication traffic delivered into the XLSMART network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916416751/en/ From left to right: Andrijanto Muljono, Director & Chief Enterprise & Strategic Relationship Officer, XLSMART; Patrick George, CEO, iBASIS This agreement is a key part of XLSMART's long-term strategy to strengthen its enterprise business and digital services. iBASIS will serve as the unique international and domestic authorized gateway for Mobile Authentication traffic into XL network prefixes. The primary benefit of this collaboration is improved security for XLSMART’s custo

SES and K2 Space to Accelerate Development of Next-Generation MEO Network16.9.2025 08:50:00 CEST | Press release

Transatlantic collaboration combines experience and agility to drive innovation in network design and delivery SES, a leading space solutions company, and K2 Space, an innovative new space technology firm, announced today a strategic collaboration to advance the development of SES’s future medium Earth orbit (MEO) network. The collaboration combines SES’s decades of experience operating global multi-orbit networks, including its O3b mPOWER MEO network, with K2 Space’s agile engineering capabilities to co-develop future network infrastructure and technologies. Earlier this year, SES and K2 Space started development activities to validate new network technologies geared for commercial and sovereign government applications. An on-orbit mission in the first quarter of 2026 will be the first step towards rolling out SES’s future MEO network. This marks a shift in the traditional satellite industry approach, moving from legacy waterfall models to an iterative process that supports continuous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye